Table 2.

Biological characteristics of injected A-NK

Patient.	Injection Site	Blood ml	PBMC1	Monocyte-depleted1	Adherent cells2	Final A-LAK recovery3	CD16+CD56+CD3+ %	CD16+CD56+CD3- %	Labeled4 cells/injection	Labeling efficiency
1	i.a.	160	1.2 × 108	8 × 107	6 × 106	5 × 108	56	13	5 × 108	58
	i.v.	160	2.8 × 108	1.5 × 108	5 × 106	1.2 × 109	59	14	5 × 108	56
2	i.a.	160	1.2 × 108	8 × 107	3.2 × 106	1.6 × 109	12	69	5 × 108	62
	i.v.	160	2.5 × 108	9 × 107	3.6 × 106	6 × 108	2	85	5 × 108	67
3	i.a.	160	1.3 × 108	5 × 107	1 × 106	6 × 108	10	60	5 × 108	55
	i.v.	160	1.3 × 108	8 × 107	5 × 106	2.3 × 109	12	69	5 × 108	42

¹ Peripheral blood mononuclear cells (PBMC) and monocyte-depleted populations were obtained from blood as described in Material and Methods.

² Cells obtained after incubation of monocyte-depleted cells in presence of the adhrence medium (Materials and Methods).

³ Number of A-NK cells recovered after fifteen days of cultures of adherent cells with rIL-2 and feeder cells as described in Materials and Methods.

⁴ A-LAK cells recovered on day fifteen were ajusted at the indicated number and labeled with ¹¹¹In-oxine before being injected i.a. or i.v.